# AZD9496 First Time in Patients Ascending Dose Study

> **NCT02248090** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 45 (actual)

## Conditions studied

- ER+ HER2- Advanced Breast Cancer

## Interventions

- **DRUG:** AZD9496
- **DRUG:** AZD9496

## Key facts

- **NCT ID:** NCT02248090
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-22
- **Primary completion:** 2017-01-31
- **Final completion:** 2019-04-03
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2019-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02248090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02248090, "AZD9496 First Time in Patients Ascending Dose Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02248090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*